Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
47 shown of 2,467 total abstracts
  1. Abstract 15282026-09-02 · 15:15 CT · S406
    Quality of life outcomes with Keytruda in patients with TNBC
    M. Krop, F. Andre, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 14092026-09-04 · 13:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-51
    A. Spira, L. Paz-Ares · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 17542026-09-03 · 16:00 CT · Arie Crown Theater
    DESTINY-Breast-159: Enhertu (trastuzumab deruxtecan) maintenance in HR+ breast cancer
    F. Andre, A. Spira, S. Antonia · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 14302026-09-05 · 20:00 CT · Arie Crown Theater
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    M. Reck, H. Rugo, J. Cortes · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 16232026-09-03 · 15:30 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-698 study)
    H. Borghaei, S. Modi, E. Winer, et al. · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 14212026-09-01 · 20:30 CT · Hall B1
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-473
    G. Curigliano, P. Schmid · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 12772026-09-04 · 13:00 CT · Arie Crown Theater
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    G. Curigliano, C. Robert, E. Winer, et al. · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 17922026-09-01 · 18:45 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    C. Saura, C. Robert, F. Andre, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 16912026-09-02 · 21:45 CT · S406
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-164
    R. Herbst, A. Spira, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 16172026-09-04 · 16:30 CT · Arie Crown Theater
    MONALEESA-767: Kisqali (ribociclib) maintenance in HR+ breast cancer
    J. Cortes, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 12322026-09-04 · 19:30 CT · E450
    KEYNOTE-216: Keytruda (pembrolizumab) neoadjuvant in TNBC
    S. Tolaney, M.C. Garassino, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 14492026-09-05 · 20:00 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-103
    G. Curigliano, J. Brahmer, A. Spira, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 13922026-09-05 · 15:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-109
    M. Reck, J. Cortes, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 19972026-09-03 · 14:45 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-635 study)
    J. Cortes, H. Rugo, M.C. Garassino · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 17112026-09-03 · 14:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-146
    J. Cortes, M. Reck · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 18212026-09-04 · 18:15 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-793
    J. Brahmer, E. Winer · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 12612026-09-02 · 15:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-879 study)
    G. Curigliano, T. Mok, J. Cortes, et al. · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 10982026-09-03 · 15:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-896 study)
    H. Borghaei, L. Paz-Ares, T. Mok, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 16952026-09-05 · 20:45 CT · Arie Crown Theater
    ASCENT-99: Trodelvy (sacituzumab govitecan) 1L in TNBC
    T. Mok, M.C. Garassino, S. Peters · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 15362026-09-02 · 20:00 CT · Arie Crown Theater
    PALOMA-196: Ibrance (palbociclib) 1L in HR+ breast cancer
    M. Reck, T. Mok, L. Paz-Ares, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract 19572026-09-03 · 15:30 CT · Hall B1
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    S. Modi, N. Rizvi, H. Borghaei, et al. · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 18002026-09-03 · 18:45 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-678 study)
    F. Andre, H. Rugo, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 18812026-09-04 · 13:00 CT · Arie Crown Theater
    PALOMA-968: Ibrance (palbociclib) 1L in HR+ breast cancer
    P. Schmid, E. Winer · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 10832026-09-01 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-900 study)
    R. Herbst, M. Reck, S. Peters, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 17742026-09-02 · 19:15 CT · Hall B1
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-981
    E. Winer, T. Mok, S. Antonia, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 10892026-09-03 · 20:45 CT · E450
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    H. Rugo, F. Andre, P. Schmid, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 14122026-09-03 · 19:15 CT · Hall B1
    OlympiA-724: Lynparza (olaparib) 1L in HR+ breast cancer
    N. Rizvi, S. Antonia, H. Borghaei, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 19152026-09-02 · 21:30 CT · E450
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-404
    H. Borghaei, T. Mok, N. Rizvi, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 16352026-09-05 · 21:30 CT · S406
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-733
    H. Rugo, E. Winer, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 11062026-09-05 · 16:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-39 study)
    H. Rugo, N. Rizvi, E. Winer, et al. · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 17832026-09-04 · 16:45 CT · S100A
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-463
    H. Rugo, M. Reck, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 19192026-09-01 · 20:00 CT · Hall B1
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    N. Rizvi, S. Antonia, J. Cortes, et al. · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 15162026-09-05 · 13:45 CT · E450
    MONALEESA-61: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    A. Spira, H. Borghaei, G. Curigliano, et al. · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 14112026-09-01 · 20:15 CT · S406
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-874
    S. Tolaney, H. Borghaei, G. Curigliano · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 14912026-09-05 · 15:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-480
    H. Rugo, S. Antonia, R. Herbst, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 14192026-09-01 · 13:15 CT · Hall B1
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    R. Herbst, J. Brahmer, G. Curigliano, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 14352026-09-01 · 21:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-440
    M. Krop, S. Antonia, H. Borghaei, et al. · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 12922026-09-05 · 16:45 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-407
    H. Rugo, H. Borghaei · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 15142026-09-04 · 14:00 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-256
    P. Schmid, C. Saura, H. Borghaei, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 14162026-09-03 · 14:45 CT · E450
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-489
    L. Paz-Ares, J. Cortes, S. Tolaney · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 19372026-09-04 · 19:15 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-592 study)
    F. Andre, J. Cortes, E. Winer · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 16972026-09-04 · 13:45 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-582
    R. Herbst, M. Reck, E. Winer · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 12322026-09-03 · 13:15 CT · E450
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-47
    S. Tolaney, M.C. Garassino, A. Spira · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 17862026-09-02 · 13:00 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    A. Spira, E. Winer · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 14652026-09-05 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-134 study)
    H. Borghaei, T. Mok · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 17352026-09-02 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-289
    E. Winer, J. Brahmer · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 19042026-09-04 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-302
    J. Cortes, G. Curigliano, S. Modi, et al. · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.